Chimigen Biomedical (Chengdu) Co., Ltd. (Chimigen), a biotech company dedicated to the development of innovative therapeutic vaccines, has closed an oversubscribed Pre-A funding round totaling nearly 170 million RMB. This round was led by SDIC Venture Capital, with participation from CAS Star, Guosheng Innovation, and existing investor Lapam Capital, among others. The funds will be used to advance the global early-stage clinical programs for its lead candidates—SN3001, a therapeutic vaccine for prostate cancer, and SN2001, a therapeutic vaccine for chronic hepatitis B—while upgrading R&D facilities and expanding its therapeutic cancer vaccine pipeline.

As Chimigen’s CRDMO partner, Genevoyager is proud to leverage its globally patented baculovirus-insect cell platform to advance multiple flagship programs within Chimigen’s pioneering SynNeogen® platform—from process development through clinical material manufacturing. We look forward to Chimigen’s continued clinical progress in delivering innovative, high-quality treatments to patients worldwide.

About Chimigen

Chimigen is a clinical-stage biotech company focused on developing next-generation immunotherapies for cancer and viral diseases. Harnessing its proprietary SynNeogen® platform, the company is advancing a diversified pipeline of therapeutic vaccines while forging global partnerships to accelerate clinical development and commercialization. Since its founding, Chimigen has secured 280 million RMB in funding from leading investors and continues to attract strategic support from top-tier venture partners. The company has received multiple accolades, including recognition as a Specialized and Innovative SME in Sichuan Province and the Excellence Award in the Future Health category of the Disruptive Technology Innovation & Entrepreneurship Competition. Driven by a commitment to innovation, breakthrough, and scientific rigor, Chimigen is dedicated to delivering high-quality, transformative therapies that improve patient outcomes worldwide.

Dr. Yuenian Shi, Founder of Chimigen, commented: “We are thrilled to receive strong support from the International Bio-town and our long-term investor Lapam Capital, following backing from SDIC Venture Capital and CAS Star earlier this year. This investment not only reflects confidence in our technology and growth prospects, but also underscores the International Bio-town’s commitment to advancing therapeutic vaccines for oncology. Based at the International Bio-town, we look forward to collaborating with partners to build a thriving ecosystem for cancer therapeutic vaccines and grow within this innovative hub. We are especially grateful to Lapam Capital for their long-term support and guidance. Chimigen remains dedicated to innovation-driven development and clinically meaningful solutions, with the goal of becoming a globally competitive leader in the therapeutic vaccine sector.”

Mr. Zhihua Yu, Chairman of Lapam Capital, said: “Chimigen is one of Lapam Capital’s key portfolio companies in the therapeutic vaccine sector. The potential of Chimigen’s SynNeogen® platform has been gradually validated as its pipeline advances, and the company’s first product, SN2001, a therapeutic vaccine for chronic hepatitis B, has recently entered clinical development. Over more than two years of partnership, we have witnessed the dedication of the Chimigen team and the emergence of its differentiated competitive advantages in the therapeutic vaccine field. Lapam Capital is delighted to continue supporting Chimigen in this financing round and looks forward to growing together with the company.”

Chengdu Guosheng Innovation stated: “Chimigen’s proprietary SynNeogen® vaccine platform combines innovative engineered fusion protein design with both first-in-class potential and strong translational value. By leveraging its breakthrough technology to activate immune responses in ‘cold tumors’, the platform aims to overcome tumor immune tolerance. The Chengdu Tianfu International Bio-town focuses on four strategic areas across 18 key tracks, providing differentiated, end-to-end ‘partnering’ services to companies. The establishment of Chimigen within the Bio-town is expected to further strengthen the cluster effect in immunotherapy, creating a closed-loop ecosystem that integrates technology translation, clinical acceleration, and industrial collaboration, while fostering a mutually empowering network between the company and the Bio-town.”

About SDIC Venture Capital

Founded in 2016, SDIC Venture Capital is a market-oriented venture capital firm established by the State Development & Investment Corporation (SDIC) to support China’s innovation-driven development strategy and promote the commercialization of scientific and technological achievements. The firm manages multiple specialized funds, including the National Science and Technology Major Project Commercialization Fund, SDIC Beijing-Tianjin-Hebei Technology Commercialization Fund, SDIC High-Tech (Shenzhen) Venture Fund, SDIC (Ningbo) Technology Commercialization Fund, and SDIC (Guangdong) Technology Commercialization Fund. Focusing on advanced manufacturing, electronics, biopharmaceuticals, and materials & energy, SDIC Venture Capital aligns its investments with national and regional development strategies, including the Beijing-Tianjin-Hebei region, the Yangtze River Delta, and the Guangdong-Hong Kong-Macao Greater Bay Area. Through these efforts, the firm aims to drive breakthroughs in key technologies and foster a vibrant ecosystem for translating scientific innovations into real-world impact.

About CAS Star

CAS Star is an early-stage investment firm focused on deep tech. Recognized as a leader in deep tech investment, the firm is committed to supporting breakthrough scientific and technological innovations. CAS Star has built an integrated ecosystem that combines research institutions, early-stage investment, entrepreneurship platforms, and post-investment support. Through this model, the firm provides tech entrepreneurs with professional, in-depth, and end-to-end solutions for funding, incubation, and growth.

About Lapam Capital

Lapam Capital is a leading Chinese venture capital firm specializing in biopharmaceuticals. The firm manages over 10 billion RMB in assets and is the only biopharma-focused investment institution to have received backing from China’s top two domestic LP funds: the National Social Security Fund and the National SME Development Fund. Lapam focuses on early- and mid-stage investments in innovative drugs and medical devices. To date, the firm has invested in more than 70 innovative drug companies and over 10 innovative medical device enterprises.

About Guosheng Innovation

Chengdu Guosheng Innovation Technology Services Co., Ltd. operates the Bio-town park, managing high-quality innovation spaces and fostering a vibrant biopharmaceutical ecosystem. The company offers end-to-end technology services for biotech enterprises and forms partnerships with professional institutions and industry leaders through contractual and equity-based collaborations. Its “four chains, one system” model—integrating industrial clustering, platform innovation, supply chain connectivity, financial support, and targeted professional services—aims to position Guosheng Innovation as a leading biotech technology service provider and comprehensive park operator in China.

About Genevoyager

Genevoyager provides one-stop CRO/CDMO services for viral vectors, proteins, and vaccines. With a proprietary technology platform for large-scale AAV production and cGMP-grade facilities, Genevoyager is dedicated to advancing healthcare by supporting our partners to develop safe, effective, affordable, and accessible protein-based products, therapeutic vaccines, and gene therapies to address unmet medical needs.

The baculovirus-insect cell expression system enables efficient and accurate protein folding with minimal glycosylation, helping designed proteins retain their intended native activity. Serum-free culture ensures high production safety, rapid scalability, and end products free of human or animal pathogens and endotoxin residues. Genevoyager’s proprietary One-Bac 4.0 system incorporates multiple globally leading patented technologies, offering significant advantages in the production of therapeutic vaccines:

● High Yield and Efficiency

Enables high-level protein expression, significantly reducing large-scale production costs for subunit vaccines, enzymes, and other biologics.

● Superior Stability and Consistency

The baculovirus seed exhibits exceptional stability, maintaining consistently high yields during large-scale manufacturing. Genevoyager’s Sf9 cell banks are free from rhabdovirus contamination, ensuring product reliability and quality.

● Rapid Scalability

Backed by a robust technology platform, an expert team, and GMP-compliant facilities meeting China, US, and EU standards, the system supports efficient scale-up for complex protein therapeutics, underpinned by stringent quality control and proven IND experience.